Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...
At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...
Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...
Novo Nordisk also boasted a 55.6% share of the GLP-1 drug space, compared to 54.4% as of August 2023. The company's most famous brands, Wegovy and Ozempic, are both GLP-1s. They have helped Novo ...
It’s not at all clear what a tariff would mean for Novo, which manufactures its medicines in facilities all over the world, ...
Novo Nordisk (NOVO) is petitioning the FDA to exclude ... which is marketed for weight loss as Wegovy and for diabetes as Ozempic. Some formulations of the drug remain on the FDA's shortage ...
Ozempic is approved for type 2 diabetes, while its counterpart, Wegovy, is approved for treating obesity. Both are made by Novo Nordisk. "Ozempic is the only version among the weekly injectables ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback